Synthesis and Characterization of Novel Calix[4]arene Schiff Base Derivatives and Cytotoxicity Effect Evaluation on Cancer Cell Lines
Abstract
In this study, four stages were used to create brand-new p-tert-butyl-calix [4] arene Schiff base derivatives. First, p-tert-butyl-phenol and formaldehyde are reacted to create p-tert-butyl-calix [4] arene (1). In the following step, methyl bromoacetate and p-ter-butyl-calix [4] arene (1) were combined with acetone and reflux to create the p-tert-butyl-calix [4] arene diester complex (2). The third step involves reacting the diester compound (2) and hydrazine hydrate to create the p-tert-butyl-calix [4] arene hydrazinamide molecule (3). In the final stage, calix [4] arene Schiff base derivatives (4a-d) were produced in good yields by combining compound (3), p-tert-butyl-calix [4] arene hydrazinamide, and various aldehyde derivatives with reflux in EtOH. Through the use of 1H-NMR, 13C-NMR, infrared spectroscopy, and elemental analysis, the structures of produced compounds were verified. Four distinct cancer lines are linked to the antitumor activity of synthetic chemicals. (HT-29, a human colon cancer cell line, PC-3, a human prostate cancer cell line, C6, a rat glioma cell line and MCF-7, a human breast cancer cell line). Weak antitumor activity was seen in synthetic substances. However, only compound 4b was found to have potential efficacy against C6 and HT-29. It is clear that compound 4b, which has a nitro substitute on the phenyl ring, draws attention due to its increased activity.
Keywords
Calix[4]arene, Anticancer activity, Schiff Base
Supporting Institution
Selcuk University Scientific Research Projects Coordinatorship (BAP)
Project Number
20111003
References
- [1] Baig S., Seevasant I., Mohamad J., Mukheem A., Huri H.Z., Kamarul T., Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?, Cell Death Dis., 7(1) (2016) 2058.
- [2] Narang A. S., & Desai D. S., Anticancer drug development, In Pharmaceutical perspectives of cancer therapeutics, New York, NY: Springer, (2009) 49-92.
- [3] Guo S., Song Y., He Y., Hu X. Y., and Wang L., Highly efficient artificial light-harvesting systems constructed in aqueous solution based on supramolecular self-assembly, Angew Chem. Int. Ed., 57 (2018) 3163–3167.
- [4] Yokoyama T., and Mizuguchi M., Crown ethers as transthyretin amyloidogenesis inhibitors, J. Med. Chem., 62 (2019) 2076–2082.
- [5] Zhang Y. M., Xu Q. Y., and Liu Y., Molecular recognition, and biological application of modified β-cyclodextrins, Sci. Chin., 62 (2019) 1–12.
- [6] Böhmer V., Calixarenes, macrocycles with (almost) unlimited possibilities, Angew. Chem. Int. Ed. Engl., 34 (2010) 713–745.
- [7] Bauer D., Andrae B., Gaß P., Trenz D., Becker S., and Kubik S., Functionalisable acyclic cucurbiturils, Org. Chem. Front., 6 (2019) 1555–1560.
- [8] Geraci C., Consoli G. M., Galante E., Bousquet E., Pappalardo M., and Spadaro A., Calix[4]arene decorated with four Tn antigenglycomimetic units and P3CS immunoadjuvant: synthesis, characterization, and anticancer immunological evaluation, Bioconjugate Chem., 19 (2008) 751–758.
- [9] Da Silva E., Lazar A. N., & Coleman A. W., Biopharmaceutical applications of calixarenes, Journal of Drug Delivery Science and Technology, 14(1) (2004) 3-20.
- [10] Yousaf A., Abd Hamid S., Bunnori N. M., & Ishola A. A., Applications of calixarenes in cancer chemotherapy: facts and perspectives, Drug design, development and therapy, 9 (2015) 2831.